. Author manuscript; available in PMC: 2017 Jan 10.

Published in final edited form as: Nature. 2013 Sep 19;501(7467):355–364. doi: 10.1038/nature12627

Table 2.

Selected worldwide large-scale clinical molecular profiling programmes by institution or consortium

Trial or programme name	Platforms or techniques	Genes and mutations	Cancer types	Tumour sample
Cancer Research UK, London

Stratified Medicine Programme¹¹²	PCR FISH	9 genes 3 genes	Melanoma, NSCLC, CRC and breast, prostate and ovarian cancer	Archival

Dana-Farber Cancer Institute, Boston, Massachusetts

PROFILE¹¹³	Sequenom	OncoMap: 41 genes, 471 mutations	All solid tumours	Archival

Curie Institute, Paris; French National Cancer Institute

SHIVA (NCT01771458)	Ion Torrent PGM CytoScan HD	AmpliSeq: 46 genes 29 genes	All solid tumours	Fresh biopsy

Gustave Roussy Institute, France (non-paediatric trials)

MOSCATO⁷⁵ (NCT01566019)	aCGH PCR	NA 96 mutations	Solid tumour phase I patients	Fresh Biopsy
SAFIR01 (NCT01414933)	aCGH PCR	NA 2 genes	Breast cancer	Fresh Biopsy
MSN	PCR FISH	Seqcan: 30 genes 5 genes	Melanoma, SCLC and NSCLC	Fresh Biopsy

Massachusetts General Hospital, Boston

NS¹¹⁴	SNaPshot	14 genes, >50 mutations	NSCLC, CRC, melanoma and breast cancer	Archival

MD Anderson Cancer Center, Houston, Texas

T9 Program¹¹⁵	Sequenom	>40 genes	All solid tumours	Archival
IMPACT⁷³ (NCT00851032)	PCR FISH	10 genes 1 gene	All solid tumours	Archival
Clearing House protocol¹¹⁶	PCR Illumina NS, Ion Torrent NS NS	~100 genes T200: 200 genes Whole genome	All solid tumours	Archival or fresh biopsy

Memorial Sloan-Kettering Cancer Center, New York

IMPACT (NCT01775072)	Illumina HiSeq Sequenom or MiSeq	275 genes (Research assays) NS (Clinical assays)	All solid tumours	Archival

Netherlands

Centre for Personalized Cancer Treatment¹¹⁷	Ion Torrent PGM 5500xl SOLiD	~150 genes >2,000 genes	Solid tumours	Fresh biopsy

Norwegian Cancer Genomics Consortium

Nationwide programme¹¹⁸	NS	Whole exome	9 tumour types, both solid and haematopoietic	Archival or fresh biopsy

Princess Margaret Cancer Centre, Toronto, Canada

IMPACT⁶⁰ (NCT01505400)	MiSeq Sequenom	TSACP: 48 genes, >700 mutations. Customized panel: 23 genes, 279 mutations	Selected solid tumours	Archival

Vall d’Hebron Institute of Oncology, Barcelona, Spain

NS72, 119	Sequenom llumina GAIIx	OncoCarta, 19 genes, 238 mutations NS	Breast cancer, solid tumour phase I patients	Archival

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

PCMI¹²⁰	SNaPshot	6–8 genes and >40 mutations	Melanoma, NSCLC, CRC and breast cancer	Archival

WIN Consortium

WINTHER⁸³ (NCT01856296)	NGS CNV CGH	NS NS NA	Solid tumours	Fresh biopsy (tumour and matched normal)

aCGH, array comparative genomic hybridization; CGH, comparative genomic hybridization; CNV, copy number variation; CRC, colorectal cancer; FISH, fluorescence in-situ hybridization; GAIIx, genome analyzer IIx; NA, not applicable; NGS, next-generation sequencing; NS, not stipulated; NSCLC, non-small-cell lung cancer; PCR, polymerase chain reaction; PCMI, personalized cancer medicine initiative; PGM, personal genome machine; SCLC, small-cell lung cancer; TSACP, TruSeq amplicon Cancer Panel.